Comparative Pharmacology
Head-to-head clinical analysis: ALDACTONE versus CAROSPIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDACTONE versus CAROSPIR.
ALDACTONE vs CAROSPIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive aldosterone receptor antagonist; increases sodium and water excretion, decreases potassium excretion at distal convoluted tubule.
Aldosterone antagonist; competitively inhibits aldosterone binding to mineralocorticoid receptors in renal distal tubules, increasing sodium and water excretion while retaining potassium. Also has weak antagonistic activity at androgen receptors.
Initial: 50-100 mg orally once daily; may increase to 100-400 mg/day in divided doses (once to twice daily).
Spironolactone 25-100 mg orally once daily. Initial: 25 mg once daily; titrate at 4-week intervals based on response and potassium levels. Maximum: 100 mg/day.
None Documented
None Documented
Spironolactone: 1.4-2.0 hours; Active metabolites (canrenone): 16.5-21.5 hours, clinically relevant for dosing interval
Spironolactone has a short half-life of 1.3-2.0 hours, but its active metabolite canrenone has a prolonged half-life of 13-24 hours (mean 18 hours), leading to a sustained pharmacodynamic effect requiring 2-3 days to reach steady state.
Renal: 50-60% as metabolites (canrenone, other sulfur-containing metabolites), minor as unchanged drug; Biliary/Fecal: ~30-40%
Approximately 50-60% of the dose is excreted in urine as active metabolites (primarily canrenone) and unchanged drug, with about 10-20% as unchanged spironolactone. Fecal excretion accounts for 20-30%, mainly as metabolites.
Category C
Category C
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic